Rubius Therapeutics Presents Preclinical Data for RTX-321, a Red Cell Therapeuticâ„¢ Oncology Product Candidate for HPV-Positive Cancers, Demonstrating its Dual Mechanism of Action
BioTech 365
OCTOBER 28, 2020
RTX-321 Induces Antigen-Specific Stimulation Combined with Broad Stimulation of Innate and Adaptive Immune Responses CAMBRIDGE, Mass., Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an … Continue reading →
Let's personalize your content